The importance of precise scientific communication: Nonrandomized trials should not be described as phase 3, and registrational-intent trials should not be described as phase 2 Editorial
| Authors: | Inman, B. A.; Vickers, A. J. |
| Title: | The importance of precise scientific communication: Nonrandomized trials should not be described as phase 3, and registrational-intent trials should not be described as phase 2 |
| Keywords: | cancer survival; overall survival; cytotoxic agent; clinical trials as topic; research design; methodology; antineoplastic agent; gastrointestinal stromal tumor; imatinib; tumor volume; editorial; oncology; health care quality; clinical trials, phase iii as topic; urinary tract cancer; interpersonal communication; terminology as topic; nomenclature; clinical trials, phase ii as topic; clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); cancer prognosis; non muscle invasive bladder cancer; humans; human; pembrolizumab; nadofaragene firadenovec; nogapendekin alfa inbakicept |
| Journal Title: | European Urology |
| Volume: | 87 |
| Issue: | 6 |
| ISSN: | 0302-2838 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2025-06-01 |
| Start Page: | 617 |
| End Page: | 618 |
| Language: | English |
| DOI: | 10.1016/j.eururo.2025.03.001 |
| PUBMED: | 40118738 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Editorial -- Source: Scopus |
